

Resource Summary Report

Generated by [dkNET](#) on Aug 30, 2026

NK-92MI

RRID:CVCL_3755

Type: Cell Line

Proper Citation

ATCC Cat# CRL-2408, RRID:CVCL_3755

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3755

Proper Citation: ATCC Cat# CRL-2408, RRID:CVCL_3755

Description: Cell line NK-92MI is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Natural killer cell lymphoblastic leukemia/lymphoma

Defining Citation: [PMID:10365666](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:35839778](#)

Comments: Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Characteristics: No longer dependent on IL2., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NK-92MI

Synonyms: NK-92 MI, NK-92 mi, NK92-MI, NK92MI, NK-92 transfected with MFG-hIL2

Cross References: CLO:CLO_0008178, ATCC:CRL-2408, BCRC:60438, cancercellines:CVCL_3755, CCRID:1102HUM-NIFDC00065, Cell_Model_Passport:SIDM01201, Cosmic-CLP:1330981, DepMap:ACH-002289, GDSC:1330981, GEO:GSM1670278, KCB:KCB 200677YJ, LINC_S_LDP:LCL-1127,

PharmacoDB:NK92MI_1160_2019, PRIDE:PXD030304, Wikidata:Q54930658

ID: CVCL_3755

Vendor: ATCC

Catalog Number: CRL-2408

Hierarchy: cvcl_2142

Record Creation Time: 20250130T072536+0000

Record Last Update: 20260830T001655+0000

Ratings and Alerts

No rating or validation information has been found for NK-92MI.

Warning: Discontinued: ATCC; PTA-6671

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Characteristics: No longer dependent on IL2., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line. **Warning:** Discontinued: BCRC; 60438

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Characteristics: No longer dependent on IL2., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yuan M, et al. (2026) Triple-Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells' Function and Facilitate Cancer Metastasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e75655.

Su Q, et al. (2026) Galectin-1-Targeted Type-I/II Photosensitizers Activate the NF- κ B Pathway to Enhance Immunity and Treat High-Risk HPV-Associated Cervical Lesions. *ACS applied materials & interfaces*, 18(2), 3599.

Gunnels TF, et al. (2026) CELLISA - a cell-cell binding assay for evaluation of nanovesicle targeting proteins. *bioRxiv : the preprint server for biology*.

Seijo-Vila M, et al. (2026) Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response. *Oncogene*, 45(25), 2436.

Shao N, et al. (2026) A high-throughput modular microfluidic platform for versatile functional assays at single-cell level. *Microsystems & nanoengineering*, 12(1).

Brennan K, et al. (2026) Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration. *Cell reports. Medicine*, 7(6), 102792.

Chen L, et al. (2025) Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma. *Pharmaceuticals (Basel, Switzerland)*, 18(5).

Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. *Cell reports. Medicine*, 6(3), 101975.

Lin YY, et al. (2025) Colorectal cancer stem cells develop NK cell resistance via homotypic cell-in-cell structures suppressed by Stathmin1. *Theranostics*, 15(10), 4308.

Cheng C, et al. (2025) Dual roles of TRPV2 in the innate immune response to cytosolic DNA: Arresting dormant and boosting activated STING. *Cell reports*, 45(1), 116745.

Tsao HW, et al. (2024) Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. *Immunity*, 57(12), 2863.

Teng HW, et al. (2024) CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer. *Molecular oncology*.

Guo S, et al. (2024) CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. *Blood advances*, 8(11), 2635.

Schober R, et al. (2023) Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure. *Journal of translational medicine*, 21(1), 791.

Kong Q, et al. (2023) Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. *Science immunology*, 8(82), eadg3196.

Perez-Hernandez D, et al. (2023) An integrated workflow for phosphopeptide identification in natural killer cells (NK-92MI) and their targets (MDA-MB-231) during immunological synapse formation. *STAR protocols*, 4(1), 102104.

Lu YC, et al. (2023) NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy. *Molecular oncology*.

Gong YY, et al. (2022) Na⁺/H⁺-exchanger 1 enhances antitumor activity of engineered NK-92 natural killer cells. *Cancer research communications*, 2(8), 842.

Figuerola-Romero C, et al. (2022) Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis. *Frontiers in immunology*, 13, 773288.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. *Cell*, 185(9), 1521.